Putting the 'A' in atypical: does α2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics?
- 1 July 1994
- journal article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 8 (4) , 193-195
- https://doi.org/10.1177/026988119400800401
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Successful Treatment of Fluvoxamine-Induced Anorgasmia by CyproheptadineThe British Journal of Psychiatry, 1994
- Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative studyActa Psychiatrica Scandinavica, 1992
- Pharmacology of saccadic eye movements in manPsychopharmacology, 1991
- Idazoxan treatment in progressive supranuclear palsyNeurology, 1991
- 5-HT2 Antagonist Ritanserin in Neuroleptic-Induced ParkinsonismClinical Neuropharmacology, 1990
- Clonidine challenge testing of alpha-2-adrenoceptor function in man: the effects of mental illness and psychotropic medicationJournal of Psychopharmacology, 1988
- Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic DrugsArchives of General Psychiatry, 1988
- The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to l-tryptophanPsychopharmacology, 1987
- Reduction of dopamine utilization in the prefrontal cortex but not in the nucleus accumbens after selective destruction of noradrenergic fibers innervating the ventral tegmental area in the ratBrain Research, 1982
- Antagonistic effect of cyproheptadine on neuroleptic-induced catalepsyPharmacology Biochemistry and Behavior, 1975